Arcutis Biotherapeutics, Inc. ARQT Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax at other companies
Other financials
Where this comes from
Reported directly by Arcutis Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.
The official record: Arcutis Biotherapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arcutis Biotherapeutics, Inc.'s debt securities, available-for-sale, accumulated gross unrealized loss, before tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arcutis Biotherapeutics, Inc.'s debt securities, available-for-sale, accumulated gross unrealized loss, before tax?
- Arcutis Biotherapeutics, Inc. (ARQT) reported debt securities, available-for-sale, accumulated gross unrealized loss, before tax of $251K in Q1 2026.
- How has Arcutis Biotherapeutics, Inc.'s debt securities, available-for-sale, accumulated gross unrealized loss, before tax changed year-over-year?
- Arcutis Biotherapeutics, Inc.'s debt securities, available-for-sale, accumulated gross unrealized loss, before tax increased by 4920.0% year-over-year, from $5K to $251K.
- What is the long-term trend for Arcutis Biotherapeutics, Inc.'s debt securities, available-for-sale, accumulated gross unrealized loss, before tax?
- Over 5 years (2020 to 2025), Arcutis Biotherapeutics, Inc.'s debt securities, available-for-sale, accumulated gross unrealized loss, before tax has grown at a 18.5% compound annual growth rate (CAGR), from $9K to $21K.